@article{MRA, author = {Yazmín Lizeth Martínez-Sánchez and Diego Moises Tavera-Zepeda and Ignacio Escobar-Munguia and Rafael Medrano-Guzmán}, title = { Clinical-epidemiological characteristic of COVID-19 and cancer, first year of pandemic}, journal = {Medical Research Archives}, volume = {12}, number = {11}, year = {2024}, keywords = {}, abstract = {At the end of 2021, 3.6% of the world´s population was infected by SARS-CoV2, which was one of the main causes of death in México with a fatality rate of 7.5%, being higher than the world average (1.9%). Patients with cancer were a vulnerable group to get infected and to have the worse results; in spite of the limited information to direct oncological treatment, medical care continued in Oncology hospitals. The objective of this study was to compare the clinical-epidemiological characteristics in patients with COVID-19 to those ruled out, who were hospitalized in a Third Level Cancer Hospital. Material and methods: A cohort of oncological cases was carried out about patients who were hospitalized within 2020-2021 with a suspected diagnosis of COVID-19 and who had a RT-PCR to rule out or to confirm the diagnosis. Data related to cancer care, respiratory symptoms, laboratory report and chest x-ray were searched in the clinical record and the cases were followed for about 30 days. Simple frequencies as well as normality tests were obtained to compare the study variables between confirmed cases and those discarded through U-Mann Whitney. Results: A total of 208 patients in which 59-year-old was the median; 49.5% were women and 50.5% were men. Colorectal cancer was the main diagnosis (19.7%). COVID-19 was confirmed in 32.2%, with dyspnea as the most common symptom (86.6%), although chills had a significant difference when comparing this group to the discarded cases, as it did elevated DHL, and an x-ray with Score≥12. During follow-up, 46.2% of patients died from this cause. Conclusions: Chills, elevated LDH and a chest x-ray with a high Score were the main differences presented in patients with cancer and COVID-19.}, issn = {2375-1924}, doi = {10.18103/mra.v12i11.6036}, url = {https://esmed.org/MRA/mra/article/view/6036} }